The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors (Q46141893)

From Wikidata

Jump to navigation Jump to search

scientific article published in July 2017

Language	Label	Description	Also known as
English	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors	scientific article published in July 2017

Statements

scholarly article

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

1 reference

Europe PubMed Central

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors (English)

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

neuroendocrine tumor

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/28609356

10

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/28609356

Joseph S Dillon

object named as

Joseph S Dillon

5

0 references

Andrew M Bellizzi

object named as

Andrew M Bellizzi

3

0 references

object named as

James R Howe

11

0 references

Thomas O'Dorisio

object named as

Thomas M O'Dorisio

8

0 references

author name string

Jonathan R Strosberg

1

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Thorvardur R Halfdanarson

2

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Jennifer A Chan

4

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Anthony P Heaney

6

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Pamela L Kunz

7

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Rodney F Pommier

12

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Kari Brendtro

13

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Mohammad A Bashir

14

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Simron Singh

15

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Michael C Soulen

16

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Laura Tang

17

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Jerome S Zacks

18

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

James C Yao

19

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Emily K Bergsland

20

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

publication date

1 July 2017

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

46

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

6

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

707-714

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Carcinoid heart disease: Diagnosis and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Elevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Hepatic-directed Therapies in Patients with Neuroendocrine Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Monitoring of Total and Regional Liver Function after SIRT.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Hepatic neuroendocrine metastases: chemo- or bland embolization?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Prognostic factors and prevention of radioembolization-induced liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/MPA.0000000000000850

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46141893&oldid=2094320547"